While Alnylam has not released an official statement regarding the financial impact of the CHMP’s recommendation, investors have responded favorably to the news. The stock’s upward movement reflects ...

The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending a change to the terms of the marketing ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to acoramidis (Beyonttra) for adult ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...